Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?

Br J Clin Pharmacol. 2022 Sep;88(9):4220-4223. doi: 10.1111/bcp.15378. Epub 2022 May 12.

Abstract

It is not clear if platelet responses are sustained after thrombopoietin receptor agonist (ar-TPO) withdrawal in paediatric patients. A multicentre retrospective observational study was performed in children with chronic immune thrombopenia (cITP) to describe ar-TPO tapering and withdrawal in patients who had achieved a sustained complete response to ar-TPOs. Ten patients (eltrombopag n = 6, romiplostim n = 4) were included. Treatment withdrawal was performed after a mean tapering time of 7.6 months. Two patients relapsed (median follow-up time of 24 months). Slow tapering and withdrawal of ar-TPOs can be safely performed in cITP paediatric patients after achieving a sustained complete response.

Keywords: drug utilization; paediatrics; platelets.

Publication types

  • Observational Study

MeSH terms

  • Benzoates / therapeutic use
  • Blood Platelets
  • Child
  • Hematologic Agents* / therapeutic use
  • Humans
  • Hydrazines / therapeutic use
  • Platelet Count
  • Purpura, Thrombocytopenic, Idiopathic* / drug therapy
  • Pyrazoles / therapeutic use
  • Receptors, Fc / therapeutic use
  • Receptors, Thrombopoietin* / agonists
  • Recombinant Fusion Proteins / therapeutic use
  • Thrombopoietin / therapeutic use

Substances

  • Benzoates
  • Hematologic Agents
  • Hydrazines
  • Pyrazoles
  • Receptors, Fc
  • Receptors, Thrombopoietin
  • Recombinant Fusion Proteins
  • Thrombopoietin
  • romiplostim
  • eltrombopag